Literature DB >> 17510508

Postnatal blocking of interferon-gamma function prevented atherosclerotic plaque formation in apolipoprotein E-knockout mice.

Mitsuhisa Koga1, Hisashi Kai, Hideo Yasukawa, Seiya Kato, Tomoka Yamamoto, Yumiko Kawai, Ken Kusaba, Yukihiko Seki, Mamiko Kai, Kensuke Egashira, Yasufumi Kataoka, Tsutomu Imaizumi.   

Abstract

It is unknown whether interferon-gamma has a positive or negative impact on atherosclerotic plaque formation. Thus, we examined the effects of postnatal interferon-gamma function blocking on plaque formation in apolipoprotein E-knockout (apoEKO) mice by overexpressing a soluble mutant of interferon-gamma receptor (sIFNgammaR), an interferon-gamma inhibitory protein. Mice were fed a Western-type diet from 8 weeks of age. sIFNgammaR or mock plasmid (control) was injected into the thigh muscle at 8 and 10 weeks' age, because serum sIFNgammaR protein was transiently increased with a peak at 2 days after a single sIFNgammaR gene transfer and remained elevated for 2 weeks. At 12 weeks' age, control apoEKO mice showed marked atherosclerotic plaques from the ascending aorta to the aortic arch. The plaques in the aortic root had massive lipid cores and macrophage infiltration with thin fibrous cap and few smooth muscle cells, demonstrating low plaque stability. In contrast, the luminal plaque area was remarkably reduced in sIFNgammaR-treated apoEKO mice. sIFNgammaR treatment not only reduced lipid core areas and macrophage infiltration but also increased smooth muscle cell count and fibrotic area, suggesting improved plaque stability. In controls, interleukin-1beta, monocyte chemoattractant protein-1, and vascular cell adhesion molecules-1 were remarkably upregulated in the aortic wall. These changes were significantly reversed by sIFNgammaR. sIFNgammaR treatment had no effects on serum cholesterol levels. In conclusion, sIFNgammaR treatment prevented plaque formation in apoEKO mice by inhibiting inflammatory changes in the arterial wall. The present study provides insight into a new strategy for preventing atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17510508     DOI: 10.1291/hypres.30.259

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  6 in total

1.  Interferon-gamma-inducible kynurenines/pteridines inflammation cascade: implications for aging and aging-associated psychiatric and medical disorders.

Authors:  Gregory F Oxenkrug
Journal:  J Neural Transm (Vienna)       Date:  2010-09-02       Impact factor: 3.575

2.  Pentoxifylline reduces tumor necrosis factor-α and HIV-induced vascular endothelial activation.

Authors:  Linden Ann Green; Chul Kim; Samir K Gupta; Gangaraju Rajashekhar; Jalees Rehman; Matthias Clauss
Journal:  AIDS Res Hum Retroviruses       Date:  2012-05-08       Impact factor: 2.205

3.  Interactive effects of interferon-gamma functional single nucleotid polymorphism (+874 T/A) with cardiovascular risk factors in coronary heart disease and early myocardial infarction risk.

Authors:  A Basak Akadam-Teker; Erhan Teker; Aynur Daglar-Aday; Kubra Cigdem Pekkoc-Uyanik; Ezgi Irmak Aslan; Özlem Kucukhuseyin; Gulcin Ozkara; Hulya Yılmaz-Aydoğan
Journal:  Mol Biol Rep       Date:  2020-10-26       Impact factor: 2.316

Review 4.  Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets.

Authors:  Dipak P Ramji; Thomas S Davies
Journal:  Cytokine Growth Factor Rev       Date:  2015-05-12       Impact factor: 7.638

Review 5.  Cytokines and atherosclerosis: a comprehensive review of studies in mice.

Authors:  Robert Kleemann; Susanne Zadelaar; Teake Kooistra
Journal:  Cardiovasc Res       Date:  2008-05-16       Impact factor: 10.787

6.  BMP4 is increased in the aortas of diabetic ApoE knockout mice and enhances uptake of oxidized low density lipoprotein into peritoneal macrophages.

Authors:  Mitsuhisa Koga; Atsushi Yamauchi; Yuki Kanaoka; Ryusuke Jige; Anna Tsukamoto; Nao Teshima; Tsuyoshi Nishioku; Yasufumi Kataoka
Journal:  J Inflamm (Lond)       Date:  2013-10-09       Impact factor: 4.981

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.